Denys–Drash Syndrome: Disease-Characteristics Research Report

Executive summary

Denys–Drash syndrome (DDS) is a very rare, usually de novo autosomal-dominant WT1-related disorder. Its canonical clinical triad is (1) congenital or early-childhood steroid-resistant nephrotic syndrome, usually caused by diffuse mesangial sclerosis (DMS); (2) predisposition to Wilms tumor; and (3) a disorder/difference of sex development (DSD), particularly gonadal dysgenesis and undervirilization in individuals with a 46,XY karyotype. Modern practice increasingly treats DDS as the severe, early-onset end of a continuous spectrum of WT1-associated nephropathy rather than as a completely discrete molecular entity. Open Targets identifies WT1 as the overwhelmingly strongest disease-associated target and maps DDS to MONDO:0008682. (OpenTargets Search: Denys-Drash syndrome-WT1, ratelade2010amurinemodel pages 1-2, ahmad2019theroleof pages 25-29)

The strongest mechanistic evidence comes from engineered mice and podocyte systems. A heterozygous WT1 zinc-finger mutation disrupts the transcriptional programs that establish and maintain podocyte identity, filtration-barrier architecture, and glomerular signaling. This produces proteinuria, DMS, and rapidly progressive kidney failure. Separately, impaired WT1-dependent genitourinary development contributes to 46,XY DSD, while loss of tumor-suppressor function in susceptible renal precursor cells predisposes to nephroblastoma. (ratelade2010amurinemodel pages 1-2)

Table: This table summarizes evidence-based, knowledge-base-ready findings for Denys-Drash syndrome across all 15 requested domains. It highlights what is supported by available human, mouse, in vitro, and registry evidence while explicitly marking unverified identifiers and data gaps.

1. Disease information

Definition. DDS is a Mendelian developmental kidney and cancer-predisposition syndrome associated with heterozygous germline pathogenic variants in WT1, encoding the WT1 transcription factor. The historical triad comprises progressive nephropathy/DMS, Wilms tumor, and 46,XY DSD (“male pseudohermaphroditism” in older literature). Not every affected person has all three manifestations; therefore, genotype-first descriptions such as WT1 disorder or WT1-associated nephropathy are now often more accurate. (ratelade2010amurinemodel pages 1-2, ahmad2019theroleof pages 25-29)

Identifiers and synonyms

• MONDO: MONDO:0008682, Denys–Drash syndrome. (OpenTargets Search: Denys-Drash syndrome-WT1)
• OMIM: commonly indexed as Denys–Drash syndrome, 194080; the causal gene is WT1, 607102. The disease number should be independently checked against the current OMIM release before automated ingestion.
• Orphanet: commonly indexed as ORPHA:220; verify against the current Orphanet release before ingestion.
• MeSH: Denys-Drash Syndrome.
• ICD: there is no sufficiently specific DDS code in routine ICD-10-CM; cases are generally represented using component codes for congenital malformation/DSD, nephrotic syndrome or kidney failure, and Wilms tumor. ICD-11 terminology should likewise be verified in the implementation being used.
• Synonyms: Drash syndrome; Denys–Drash syndrome; DDS; WT1-related Denys–Drash syndrome; nephropathy–Wilms tumor–genital anomaly syndrome.

The evidence base is principally aggregated disease resources, small retrospective cohorts, registries, individual clinical cases, tumor series, and engineered models—not population-scale EHR epidemiology.

2. Etiology and risk factors

Primary cause

DDS is caused chiefly by a heterozygous germline WT1 pathogenic variant. Classic DDS variants are missense substitutions in exons 8 or 9, which encode zinc fingers 2 and 3 of the DNA-binding domain. Historical molecular series found WT1 variants in 10/17 and 6/8 clinically diagnosed patients, illustrating both the central role of WT1 and the limitations of early testing methods. (ahmad2019theroleof pages 25-29)

Most cases are sporadic and presumed or demonstrated de novo. A person carrying a pathogenic variant has an autosomal-dominant transmission risk of 50% for each pregnancy, although reproductive fitness may be reduced by severe childhood disease or gonadal dysgenesis.

Variant and phenotype considerations

• Classic DDS: predominantly zinc-finger missense variants, often in exons 8–9. Recurrent substitutions include variants affecting Arg394, such as p.Arg394Trp in the historical numbering used by the mouse-model literature. (ratelade2010amurinemodel pages 1-2)
• Frasier syndrome: classically intron 9 donor-region variants that alter the +KTS/−KTS splice-isoform ratio; usually later nephropathy, FSGS, 46,XY gonadal dysgenesis, and gonadoblastoma risk, with a lower Wilms-tumor risk than classic DDS.
• Truncating/deletion variants: may produce Wilms tumor predisposition, nephropathy, genital anomalies, or overlapping phenotypes. Thus, variant class predicts risk imperfectly.
• Population frequency: fully penetrant classic DDS variants should be absent or exceptionally rare in reference populations such as gnomAD. Variant-specific gnomAD and ClinVar records must nevertheless be checked individually.

Open Targets also reports low-scoring associations with GPC3 and WTIP, but these should not be encoded as established primary DDS genes. GPC3 is relevant to an overlapping Wilms-tumor/overgrowth differential, and WTIP is biologically connected to WT1/podocyte pathways; WT1 remains the definitive causal gene. (OpenTargets Search: Denys-Drash syndrome-WT1)

Environmental, protective, and gene–environment factors

No toxin, lifestyle exposure, nutritional factor, or infectious agent is established as a cause of DDS. No reproducible protective allele or environmental exposure is known to prevent expression of a pathogenic WT1 variant. Clinical severity may be affected by general modifiers of kidney injury—blood pressure, infections, nephrotoxins, and treatment—but these are downstream modifiers rather than causes. Formal DDS-specific gene–environment studies are lacking.

3. Phenotypes

The most reproducible timing statement is that DMS-associated renal disease begins in infancy or early childhood and commonly progresses to end-stage kidney disease before age five. (ratelade2010amurinemodel pages 1-2) Exact percentages for each triad component vary markedly with ascertainment and variant class; historical statements that nearly all DDS patients develop Wilms tumor should not be applied to all molecularly diagnosed WT1-nephropathy patients. (ahmad2019theroleof pages 25-29)

Quality of life. No validated DDS-specific EQ-5D, SF-36, PROMIS, or utility dataset was identified. Expected burdens include edema and dietary/fluid restrictions, frequent laboratory and imaging visits, dialysis, major surgery, cancer treatment, transplantation and immunosuppression, fertility concerns, and psychosocial effects of DSD care. These impacts are clinically compelling but inadequately quantified in DDS-specific cohorts.

4. Genetic and molecular information

• Gene: WT1, chromosome 11p13; HGNC:12796; NCBI Gene:7490; OMIM gene entry 607102.
• Protein: WT1 transcription factor, a nuclear zinc-finger DNA/RNA-binding regulator with multiple isoforms, notably +KTS and −KTS.
• Origin: usually constitutional germline; a second somatic alteration or other cooperating event can occur in tumor tissue. A germline result should not be confused with tumor-only somatic WT1 alteration.
• Mechanism: classic zinc-finger missense variants impair sequence-specific DNA binding and may exert dominant-negative effects on wild-type WT1. Mouse evidence also supports a dosage or threshold model in which residual normal WT1 activity determines podocyte stability. (ratelade2010amurinemodel pages 1-2)
• Classification: recurrent zinc-finger variants with established DDS cases are generally pathogenic/likely pathogenic; novel variants require ACMG/AMP assessment using population rarity, de novo status, phenotype specificity, functional evidence, and segregation. A VUS alone does not establish DDS.
• Chromosomal abnormalities: larger 11p13 deletions involving WT1 cause WAGR-spectrum disease rather than classic DDS. Karyotype or chromosomal microarray is useful when syndromic features suggest a deletion, but most classic DDS cases have sequence-level variants.
• Modifier genes/epigenetics: no clinically validated modifier gene or DDS-specific constitutional epigenetic signature is established. Tumor evolution may involve additional genetic and epigenetic events, but these are not diagnostic of the constitutional syndrome.

5. Environmental information

Environmental toxins, radiation, smoking, alcohol, diet, occupation, and infectious agents are not recognized initiating factors. Avoiding nephrotoxins, controlling blood pressure, maintaining appropriate nutrition, and preventing infection are tertiary renal-care measures, not primary prevention of DDS. There is no zoonotic or transmissible component.

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous germline WT1 pathogenic variant leads to reduced or qualitatively abnormal WT1 transcription-factor activity in developing renal and gonadal tissues.
2. Abnormal WT1 activity leads to impaired regulation of nephron-progenitor renewal, mesenchymal-to-epithelial transition, and podocyte differentiation/maintenance.
3. Impaired podocyte programs lead to altered slit-diaphragm, actin-cytoskeleton, focal-adhesion, polarity, and paracrine angiogenic/growth-factor signaling.
4. Podocyte dysfunction results in filtration-barrier failure, heavy proteinuria, and nephrotic syndrome.
5. Continued podocyte and mesangial injury leads to DMS/glomerulosclerosis, nephron loss, CKD, and early kidney failure.
6. Branch A: defective WT1-dependent sex determination and gonadal development leads to 46,XY gonadal dysgenesis and undervirilized/ambiguous external genitalia.
7. Branch B: constitutional loss of WT1 tumor-suppressor competence plus additional renal-cell events—this second-event sequence is partly inferred and varies by tumor—leads to nephrogenic precursor persistence and Wilms tumor.

Molecular and cellular detail

WT1 regulates FGF and BMP–pSMAD signaling, the developmental regulators SALL1 and PAX2, and mesenchymal-to-epithelial transition through FGF8 and WNT4. In podocytes, WT1 helps establish identity through MAFB, LMX1B, FOXC2, and TCF21, coordinating cytoskeletal, slit-diaphragm, polarity, and basement-membrane attachment programs. These relationships derive substantially from developmental and model evidence and should therefore be annotated as mechanistic support rather than direct proof in every human DDS kidney. (ratelade2010amurinemodel pages 1-2)

The p.Arg394Trp knock-in mouse developed DMS-like disease and early renal failure and revealed altered glomerular expression of candidate WT1 targets including Scel, Sulf1, and Cyp26a1. The authors described the work as providing insight into “early mechanisms leading to glomerular” disease and concluded that the results support a threshold/dominant-negative model of WT1 function. (ratelade2010amurinemodel pages 1-2)

Suggested annotations

• Biological processes: GO:0072006 nephron development; GO:0032835 glomerulus development; GO:0006355 regulation of DNA-templated transcription; GO:0007275 multicellular organism development; mesenchymal-to-epithelial transition and kidney epithelium development terms should be release-checked.
• Molecular function: GO:0003700 DNA-binding transcription-factor activity; GO:0000976 transcription cis-regulatory-region binding.
• Cell types: CL:0000653 podocyte; CL:0000099 mesangial cell; nephron progenitor cell and gonadal supporting-cell terms should be checked against the current CL release.
• Cellular component: GO:0005634 nucleus; GO:0005923 bicellular tight junction is not a precise substitute for the slit diaphragm, so a current slit-diaphragm term should be used where available.

No validated DDS metabolomic or lipidomic diagnostic signature exists. Human single-cell/spatial studies specifically resolving classic DDS remain emerging; consequently, most current cell-state conclusions come from engineered models, bulk glomerular profiling, and podocyte culture rather than large human single-cell cohorts.

7. Anatomical structures affected

• Primary: kidneys (UBERON:0002113), renal glomeruli (UBERON:0001285), podocytes, mesangial compartment, and developing nephrogenic tissue.
• Genital/reproductive: gonads (UBERON:0000473), testes or dysgenetic/streak gonads, and internal/external genital structures in 46,XY DSD.
• Tumor site: one or both kidneys; bilateral or multifocal disease can occur in predisposition syndromes.
• Subcellular: WT1 acts primarily in the nucleus (GO:0005634); downstream dysfunction affects the podocyte actin cytoskeleton, cell–matrix adhesions, and slit diaphragm.

DMS is intrinsically diffuse and generally bilateral at the glomerular level. Wilms tumor, by contrast, can be unilateral, bilateral, or multifocal.

8. Temporal development

The constitutional lesion is present from conception, while phenotypic expression is developmental and age dependent. Genital differences are congenital. Proteinuria/nephrotic syndrome usually becomes evident congenitally, in infancy, or early childhood. DMS progresses chronically and often rapidly to kidney failure before age five. (ratelade2010amurinemodel pages 1-2)

A French transplant-study protocol reports a median kidney-transplant age of 3.6 years, consistent with aggressive early renal progression. (NCT07605884 chunk 1) There is no spontaneous renal remission in established DMS; apparent pharmacologic responses in isolated reports should not be generalized. The critical intervention window is therefore before irreversible kidney failure or advanced tumor development: prompt WT1 testing, renal monitoring, tumor surveillance, and multidisciplinary planning.

9. Inheritance and population

DDS is autosomal dominant but commonly de novo. Penetrance is high for some WT1-associated phenotype, but penetrance of each individual component—DMS, Wilms tumor, or DSD—is incomplete and variant dependent. Expressivity is substantial, even among people grouped under WT1-related disease. Genetic anticipation is not recognized. Parental germline mosaicism is possible even when parental blood tests are negative, but its frequency is unknown.

No credible population prevalence, annual incidence, carrier frequency, founder effect, ethnic enrichment, or consanguinity effect was identified. DDS occurs worldwide and across ancestry groups. Apparent sex ratios depend on whether sex is classified by chromosomes, gonads, phenotype, or sex assignment; DSD ascertainment particularly enriches reported 46,XY cases. The disease is too rare and inconsistently defined historically for a robust cases-per-100,000 estimate.

10. Diagnostics

Recommended approach

1. Recognize the phenotype: early steroid-resistant nephrotic syndrome, DMS, Wilms tumor at a young age, bilateral/multifocal Wilms tumor, or unexplained 46,XY DSD.
2. Renal evaluation: urinalysis and urine protein/creatinine ratio; serum albumin, creatinine/eGFR, electrolytes; blood pressure; edema and nutritional assessment.
3. Imaging: renal ultrasonography to assess tumor, nephrogenic rests, kidney size, and structural disease. MRI is preferred when more detailed tumor characterization is needed without ionizing radiation.
4. Pathology: biopsy typically shows DMS—mesangial-matrix expansion and sclerosis involving glomeruli—although biopsy can be avoided when genetic and clinical evidence is definitive or procedural risk is excessive.
5. Molecular confirmation: sequence and deletion/duplication analysis of WT1. A comprehensive steroid-resistant nephrotic syndrome/Wilms-predisposition panel is appropriate when the phenotype is atypical.
6. DSD evaluation: chromosome analysis or rapid sex-chromosome assessment, pelvic/abdominal imaging, gonadal and adrenal hormone testing as clinically indicated, and multidisciplinary endocrinology/urology/genetics review.
7. Tumor genetics: paired germline/tumor analysis can clarify constitutional predisposition and acquired tumor events but is not required to diagnose nephropathy.

WES/WGS. Exome or genome sequencing is useful if targeted testing is negative, if the phenotype overlaps another monogenic podocytopathy, or if structural/noncoding variation is suspected. Genome sequencing may better detect complex structural and selected intronic variants, but targeted WT1 analysis remains efficient for a classic presentation.

CMA/karyotype/FISH. CMA is appropriate for suspected 11p13 deletion/WAGR. Karyotype is important for DSD assessment. FISH has a limited confirmatory role. Mitochondrial and repeat-expansion testing are not routine DDS tests.

Differential diagnosis: Frasier syndrome and other WT1-related nephropathies; WAGR; isolated DMS; NPHS1/NPHS2/LAMB2/PLCE1 and other genetic nephrotic syndromes; Simpson–Golabi–Behmel syndrome; Beckwith–Wiedemann spectrum; sporadic Wilms tumor; and other causes of 46,XY DSD. Distinction increasingly rests on molecular diagnosis rather than requiring the complete historical triad.

11. Outcome and prognosis

Untreated nephropathy is progressive and typically culminates in childhood kidney failure. Long-term morbidity arises from dialysis, transplantation, tumor therapy, hypertension, CKD-mineral/bone disease, growth impairment, gonadal dysfunction, infertility, and psychosocial effects. DDS-specific five- and ten-year survival estimates were not found and should not be inferred from general Wilms-tumor survival statistics.

Kidney transplantation can provide durable renal replacement because the intrinsic podocytopathy does not usually recur in a genetically normal graft. However, tumor status and native-kidney management must be addressed first. A current French observational protocol cites 20% PTLD risk in DDS recipients versus approximately 4% in general transplant populations, and a median transplantation age of 3.6 years; these figures are cohort/protocol observations, not universal rates. (NCT07605884 chunk 1)

Prognosis depends on variant class, age and rate of renal decline, Wilms-tumor stage/histology and bilaterality, treatment toxicity, DSD/gonadal-tumor issues, transplantation access, and post-transplant complications. No validated molecular prognostic score exists.

12. Treatment and current applications

There is no approved therapy that corrects WT1 dysfunction.

Renal management

• Salt/fluid management, individualized nutrition, edema treatment, vaccination, and blood-pressure control.
• ACE-inhibitor or angiotensin-receptor-blocker therapy may reduce proteinuria when blood pressure, kidney function, and potassium permit; these are supportive rather than curative.
• Genetic DMS is generally steroid resistant. Prolonged empiric glucocorticoids or other immunosuppression should be avoided once a monogenic WT1 podocytopathy is established unless another indication exists.
• Dialysis is used for kidney failure or as a bridge to transplantation.
• Unilateral or bilateral nephrectomy is individualized according to tumor status, severe protein loss/hypertension, residual function, and transplant planning.
• Kidney transplantation is definitive renal replacement after oncologic assessment; genetic disease recurrence in the graft is not expected.

Suggested NCIT interventions: Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker, Dialysis, Nephrectomy, and Kidney Transplantation; exact NCIT codes should be release-validated.

Wilms tumor and DSD management

Wilms tumor is treated according to pediatric oncology risk, stage, histology, laterality, and cooperative-group protocol, using surgery plus chemotherapy, with radiotherapy for selected risk groups. Nephron-sparing strategies are particularly important for bilateral disease but must be balanced against oncologic control and already progressive DMS.

DSD management requires pediatric endocrinology, urology/surgery, genetics, psychology, nephrology, oncology, and ethics expertise. Gonadal management is individualized according to gonadal location/function, malignancy risk, the person’s values, and contemporary DSD standards; irreversible procedures should not be reduced to the older diagnosis label alone.

Experimental therapy and trials

No DDS-specific gene therapy, CRISPR, RNA therapy, cell therapy, or targeted pharmacologic intervention was identified in clinical trials. Current real-world research is observational:

• NCT01252901: WT1-mutation-associated disease registry; completed; 52 participants.
• NCT06065852: UK National Registry of Rare Kidney Diseases; recruiting; target enrollment 35,000.
• NCT01793168: rare-disease registry/natural-history study; recruiting; target enrollment 20,000.
• NCT07605884: planned 108-participant observational case-control study of PTLD risk after transplantation in DDS. The protocol analyzes French data from 2000–2022. (NCT07605884 chunk 1)

These studies support natural-history and safety characterization but do not establish treatment efficacy.

13. Prevention

Primary prevention: no lifestyle or vaccine can prevent a de novo WT1 variant. Reproductive options after identification of a familial variant include genetic counseling, prenatal diagnosis, and IVF with preimplantation genetic testing for monogenic disease.

Secondary prevention: molecular diagnosis, cascade testing, renal monitoring, and Wilms-tumor surveillance can identify complications earlier. Common expert practice is renal ultrasonography approximately every three months through the principal childhood risk window, but the exact stopping age and protocol should follow the responsible cancer-predisposition guideline and variant-specific risk assessment rather than an unreferenced universal rule.

Tertiary prevention: aggressive CKD and hypertension management; avoidance of nephrotoxins; dialysis/transplant planning; vaccination before transplantation; tumor follow-up; DSD and gonadal surveillance; and monitoring for immunosuppression-related EBV/PTLD. The PTLD signal in the French protocol makes EBV-risk assessment and post-transplant viral monitoring especially important, although the magnitude requires confirmation. (NCT07605884 chunk 1)

14. Other species and natural disease

No well-established naturally occurring veterinary DDS counterpart was identified. DDS is not infectious, transmissible, or zoonotic. WT1 orthologs and renal-development functions are evolutionarily conserved, making engineered animals scientifically useful, but this does not constitute natural disease in those species.

15. Model organisms and advanced research

The most informative system is Mus musculus (NCBI Taxon:10090). Knock-in mice carrying the DDS-associated Wt1 p.Arg394Trp allele reproduce key renal features, including podocyte dysfunction, DMS/glomerulosclerosis, proteinuria, and early renal failure. Isolated-glomerulus expression profiling identified Scel, Sulf1, and Cyp26a1 as altered candidate WT1 targets. This is strong causal model evidence, although timing, genetic background, and complete tumor/DSD penetrance differ from human disease. (ratelade2010amurinemodel pages 1-2)

Additional models include Wt1 hypomorphic, knockout/conditional-knockout, and truncating-allele mice; immortalized human podocytes derived from DDS patients; transfected podocyte systems for DNA-binding/localization assays; and kidney organoids or iPSC systems as emerging platforms. Patient-podocyte proteomics and model transcriptomics indicate dedifferentiation and cytoskeletal/signaling abnormalities, but no proteomic, metabolomic, or epigenomic signature is clinically validated.

Recent developments and expert assessment

The major 2023–2024 conceptual development is the move from rigid eponymous categories toward a WT1-related disorder spectrum, integrating genotype, age at nephropathy, histology, DSD, and tumor risk. A 2024 review, WT1-related disorders: more than Denys–Drash syndrome, reflects this shift (López-González and Ariceta, Pediatric Nephrology, published online February 2024; DOI: https://doi.org/10.1007/s00467-024-06302-y). A 2024 review of developmental FSGS likewise emphasizes genetically defined podocytopathies and transplantation rather than treating the biopsy pattern as a stand-alone disease (Klomp et al., March 2024; DOI: https://doi.org/10.1159/000538345).

The practical expert interpretation is that DDS should be considered a high-risk clinical presentation of germline WT1 dysfunction, not a diagnosis requiring every element of the classic triad. Early genomic diagnosis can prevent ineffective immunosuppression, trigger tumor and DSD evaluation, guide family counseling, and permit coordinated oncologic and transplant planning. This interpretation is consistent with the strong WT1–DDS association and with model evidence connecting defective WT1 dosage/function directly to podocyte failure. (OpenTargets Search: Denys-Drash syndrome-WT1, ratelade2010amurinemodel pages 1-2)

Key evidence quotations and references

1. Ratelade et al., 2010, Human Molecular Genetics. DOI: https://doi.org/10.1093/hmg/ddp462. The study describes DDS as involving “early-onset nephrotic syndrome, male pseudohermaphroditism, and Wilms tumor predisposition,” reports that DMS generally reaches renal failure before age five, and provides p.Arg394Trp mouse-model evidence for a WT1 activity-threshold/dominant-negative mechanism. (ratelade2010amurinemodel pages 1-2)
2. Historical human genetics summarized in the retrieved literature: Pelletier et al. identified WT1 variants in 10/17 DDS patients, while Baird et al. detected heterozygous germline variants in 6/8; the characteristic lesions clustered in exons 8–9. (ahmad2019theroleof pages 25-29)
3. Open Targets, accessed through the research tool: WT1 had five disease-evidence records and an association score of 0.853 for MONDO:0008682, far exceeding GPC3 or WTIP. Supporting PubMed records listed by the resource include PMID 1302008, 1658787, 1655284, 1327525, 8388765, 10571943, 9499425, 9529364, 9607189, 11182928, and 24402088. (OpenTargets Search: Denys-Drash syndrome-WT1)
4. NCT07605884, ClinicalTrials.gov, 2026 protocol record. The study reports a French-cohort signal of 20% PTLD in DDS transplant recipients versus 4% in general transplant populations and median transplant age 3.6 years; these data require prospective or independent confirmation. (NCT07605884 chunk 1)

Evidence limitations

DDS is exceptionally rare, historical clinical definitions are inconsistent, and modern molecular cohorts often combine DDS, Frasier syndrome, isolated WT1 nephropathy, and other WT1 disorders. Consequently, many commonly repeated penetrance and tumor-risk percentages are ascertainment-sensitive. Recent 2023–2024 sources are mainly expert reviews rather than DDS-specific prospective cohorts. No randomized therapeutic trial, validated quality-of-life instrument, robust population incidence estimate, DDS-specific multi-omics diagnostic signature, or clinically established disease-modifying therapy was identified.

References

1. (OpenTargets Search: Denys-Drash syndrome-WT1): Open Targets Query (Denys-Drash syndrome-WT1, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (ratelade2010amurinemodel pages 1-2): Julien Ratelade, Christelle Arrondel, Ghislaine Hamard, Serge Garbay, Scott Harvey, Nathalie Biebuyck, Herbert Schulz, Nick Hastie, Marco Pontoglio, Marie-Claire Gubler, Corinne Antignac, and Laurence Heidet. A murine model of denys-drash syndrome reveals novel transcriptional targets of wt1 in podocytes. Human molecular genetics, 19 1:1-15, Sep 2010. URL: https://doi.org/10.1093/hmg/ddp462, doi:10.1093/hmg/ddp462. This article has 50 citations and is from a domain leading peer-reviewed journal.

3. (ahmad2019theroleof pages 25-29): AH Bin Ahmad. The role of wt1 in nephron endowment and glomeruloscerosis (gs)/chronic kidney disease (ckd). Unknown journal, 2019.

4. (NCT07605884 chunk 1): Denys-Drash Syndrome and Risk of Post-transplant Lymphoproliferative Disorder. Assistance Publique - Hôpitaux de Paris. 2026. ClinicalTrials.gov Identifier: NCT07605884

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0000093 (2 mentions) - the report calls it "Laboratory abnormality; congenital, infantile, or early childhood; persistent and progressive"; HP calls it Proteinuria
• HP:0005567 (2 mentions) - the report calls it "Biopsy manifestation; severe and progressive, often leading to kidney failure before age five"; HP calls it Renal magnesium wasting
• HP:0002667 (2 mentions) - the report calls it "Renal malignancy, commonly early childhood; may be unilateral or bilateral/multifocal"; HP calls it Nephroblastoma
• GO:0005634 (3 mentions) - the report calls it "Subcellular: WT1 acts primarily in the nucleus"; GO calls it nucleus**
• HP:0000822 (1 mention) - the report calls it "Secondary renal sign; frequency increases with progressive CKD"; HP calls it Hypertension
• HP:0000790 (1 mention) - the report calls it "Possible urinary abnormality, less defining than proteinuria"; HP calls it Hematuria

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• UBERON:0002113 (2 mentions) - the report calls it "Primary: kidneys"; UBERON calls it kidney**, and lists "reniculate kidney" among its other names
• UBERON:0000473 (2 mentions) - the report calls it "Genital/reproductive: gonads"; UBERON calls it testis**, and lists "gonad of male reproductive system" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Taxon, ORPHA, Gene.